Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology

Treating AU: The Rise of JAK Inhibitors

At a Glance

JAK inhibitors are powerful, newly approved medications that can promote significant hair regrowth for many patients with Alopecia Universalis. However, they require long-term use to maintain results and carry strict FDA boxed warnings for serious potential side effects.

The treatment of Alopecia Universalis (AU) has undergone a dramatic transformation in recent years. For a long time, AU was considered “refractory,” meaning it often failed to respond to older, conventional treatments like oral steroids (prednisone) or contact immunotherapy (applying irritating chemicals to the skin) [1][2]. Today, a new class of medications called JAK inhibitors has changed the landscape, offering the possibility of significant hair regrowth for many patients [3][4].

The Shift to JAK Inhibitors

JAK inhibitors work by blocking the JAK-STAT pathway, a cellular communication line that your immune system uses to send “attack” signals to your hair follicles [5][6]. By “hanging up the phone” on these signals, these medications stop the inflammatory feedback loop driven by proteins like IFN-gamma and IL-15 [5][6].

Several medications in this class are now used for severe hair loss:

Medication Mechanism Approval Status
Baricitinib JAK1/JAK2 inhibitor FDA-approved for severe alopecia in adults [3]
Ritlecitinib JAK3/TEC kinase inhibitor FDA-approved for severe alopecia in ages 12 and older [4][7]
Tofacitinib Pan-JAK inhibitor Often used “off-label” for alopecia [8][9]

Measuring Success and Timelines

Doctors often use the SALT score (Severity of Alopecia Tool) to track treatment progress. A SALT score of 100 means total hair loss, while 0 means a full head of hair.

Realistic Timelines: Hair regrowth is not immediate. It often takes 3 to 6 months of continuous use to see the first signs of “peach fuzz” or meaningful regrowth, and up to a year for maximum results [3][10].

Important Context for AU: It is important to note that patients with Alopecia Universalis—who have total body hair loss and often longer-standing disease—may experience lower response rates or require longer treatment times compared to those with patchy hair loss [3][10].

Furthermore, these drugs are not a “cure” but a way to manage the disease. Studies show a high rate of relapse or hair loss recurrence once treatment is discontinued [11][12]. For this reason, many patients and doctors view this as a maintenance therapy that requires long-term use [13].

FDA Black Box Warnings and Side Effects

While JAK inhibitors can be highly effective, they are powerful systemic medications that require careful consideration. JAK inhibitors carry FDA “boxed warnings” (the strictest safety warning). Because they modulate the immune system, they carry risks for:

  • Serious or fatal infections (including reactivating tuberculosis or shingles) [14][15]
  • Malignancies (an increased risk of certain cancers) [14][15]
  • Major Adverse Cardiovascular Events (MACE) (such as heart attacks or strokes) [14][15]
  • Thrombosis (blood clots in the deep veins or lungs) [14][15]

Your doctor will carefully screen your health history to ensure these medications are safe for you. More common, less severe side effects include acne, upper respiratory infections, headaches, and changes in your lipid (cholesterol) levels [16][17].

Decision Factors

Choosing a treatment for AU is a personal decision that balances the desire for hair regrowth with the commitment to long-term medication and its associated risks [18][19]. Have an honest conversation with your doctor about your complete health profile to determine if a JAK inhibitor is the right path for you.

Common questions in this guide

How long does it take for JAK inhibitors to regrow hair?
Hair regrowth with JAK inhibitors is not immediate. It typically takes 3 to 6 months of continuous daily use to see the first signs of regrowth, and up to a year to achieve maximum results.
Will my hair fall out if I stop taking a JAK inhibitor?
Yes, studies show a high rate of hair loss recurrence if the medication is discontinued. Because JAK inhibitors manage the disease rather than cure it, they are generally considered a long-term maintenance therapy.
What are the risks or side effects of JAK inhibitors for alopecia?
While effective, these drugs are powerful immune system modulators that carry FDA boxed warnings. Potential severe risks include serious infections, cardiovascular events, blood clots, and an increased risk of certain malignancies.
Which JAK inhibitors are approved for treating severe alopecia?
Currently, baricitinib is FDA-approved for adults with severe alopecia, and ritlecitinib is approved for patients ages 12 and older. Other medications, like tofacitinib, are sometimes prescribed off-label by dermatologists.
What is a SALT score?
The Severity of Alopecia Tool (SALT) score is a measurement doctors use to track hair loss and monitor treatment progress over time. A score of 100 indicates total hair loss, while a score of 0 means a full head of hair.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my SALT score, how severe is my hair loss compared to other patients you've treated with JAK inhibitors?
  2. 2.Which specific JAK inhibitor do you recommend for my case, and is it FDA-approved for my age group?
  3. 3.How will we monitor my blood work (lipids, CPK, liver enzymes) while I am on this medication?
  4. 4.What is the 'exit strategy' if the medication works? Can we taper the dose, or is this a lifelong commitment?
  5. 5.How do my personal risk factors for infections, blood clots, or cardiovascular issues affect my eligibility given the FDA black box warnings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

    Liu LY, Craiglow BG, Dai F, King BA

    Journal of the American Academy of Dermatology 2017; (76(1)):22-28 doi:10.1016/j.jaad.2016.09.007.

    PMID: 27816293
  2. 2

    [Efficacy and safety of baricitinib treatment in alopecia areata: a retrospective analysis].

    Rózsa P, Szász Z, Asztalos L, et al.

    Orvosi hetilap 2025; (166(49)):1943-1948 doi:10.1556/650.2025.33444.

    PMID: 41353672
  3. 3

    Two Phase 3 Trials of Baricitinib for Alopecia Areata.

    King B, Ohyama M, Kwon O, et al.

    The New England journal of medicine 2022; (386(18)):1687-1699 doi:10.1056/NEJMoa2110343.

    PMID: 35334197
  4. 4

    Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.

    Mesinkovska N, King B, Zhang X, et al.

    The Journal of dermatology 2024; (51(11)):1414-1424 doi:10.1111/1346-8138.17442.

    PMID: 39328096
  5. 5

    The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.

    Crowley EL, Fine SC, Katipunan KK, Gooderham MJ

    Journal of cutaneous medicine and surgery 2019; (23(3)):289-297 doi:10.1177/1203475418824079.

    PMID: 30688081
  6. 6

    Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.

    Qi F, Liu F, Gao L

    Frontiers in immunology 2021; (12()):790125 doi:10.3389/fimmu.2021.790125.

    PMID: 34868078
  7. 7

    Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.

    Thaçi D, Tziotzios C, Ito T, et al.

    Dermatology and therapy 2023; (13(11)):2621-2634 doi:10.1007/s13555-023-00997-x.

    PMID: 37707764
  8. 8

    Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.

    Gordon SC, Abudu M, Zancanaro P, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(4)):e156-e157 doi:10.1111/jdv.15383.

    PMID: 30520145
  9. 9

    Excellent response to tofacitinib treatment in a patient with alopecia universalis.

    Erduran F, Adışen E, Aksakal AB

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2017; (26(2)):47-49 doi:10.15570/actaapa.2017.15.

    PMID: 28632888
  10. 10

    Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

    Ramírez-Marín HA, Tosti A

    Drug design, development and therapy 2022; (16()):363-374 doi:10.2147/DDDT.S334727.

    PMID: 35210753
  11. 11

    Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.

    Zheng C, Tosti A

    Dermatologic clinics 2021; (39(3)):407-415 doi:10.1016/j.det.2021.03.005.

    PMID: 34053594
  12. 12

    Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.

    Yu DA, Kim YE, Kwon O, Park H

    Indian journal of dermatology, venereology and leprology 2021; (87(5)):621-627.

    PMID: 34379968
  13. 13

    Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.

    King B, Ko J, Kwon O, et al.

    JAMA dermatology 2024; (160(10)):1075-1081 doi:10.1001/jamadermatol.2024.2734.

    PMID: 39141364
  14. 14

    Baricitinib as the first systemic treatment for severe alopecia areata.

    Kincaid CM, Arnold JD, Mesinkovska NA

    Expert review of clinical immunology 2023; (19(6)):565-573 doi:10.1080/1744666X.2023.2200166.

    PMID: 37042112
  15. 15

    Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis.

    Xu Q, He L, Yin Y

    Frontiers in pharmacology 2023; (14()):1241954 doi:10.3389/fphar.2023.1241954.

    PMID: 37614317
  16. 16

    Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.

    Papierzewska M, Waśkiel-Burnat A, Rudnicka L

    Clinical drug investigation 2023; (43(5)):325-334 doi:10.1007/s40261-023-01260-z.

    PMID: 37138134
  17. 17

    Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.

    De Greef A, Thirion R, Ghislain PD, Baeck M

    Dermatology and therapy 2023; (13(11)):2869-2877 doi:10.1007/s13555-023-01030-x.

    PMID: 37717224
  18. 18

    Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.

    Huang J, Qian P, Tang Y, et al.

    Acta dermato-venereologica 2023; (103()):adv12425 doi:10.2340/actadv.v103.12425.

    PMID: 38112208
  19. 19

    Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.

    Bushwereb R, Srivastava G

    Italian journal of dermatology and venereology 2024; (159(4)):380-389 doi:10.23736/S2784-8671.24.07894-0.

    PMID: 38780910

This page explains JAK inhibitor treatments for Alopecia Universalis for educational purposes only. Always consult your dermatologist to determine if these systemic medications and their associated risks are appropriate for your specific health profile.

Get notified when new evidence is published on Alopecia universalis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.